Reviews/Novel Antibiotics/Dalbavancin achieves high cure rates in acute bacterial skin infections
Lipoglycopeptides · NOVEL-AB-LIPOGLY-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Two large randomised trials tested once-weekly dalbavancin against standard antibiotics for serious skin infections and found it worked about as well. In one trial roughly 89% of patients were judged cured at the follow-up visit and over 90% at the end of treatment [1]; in the other, about 80% showed an early favourable response and about 91% of those with staph infections did well [3]. Two smaller real-world hospital reports back this up by showing few patients needed admission [7] or had the infection come back [10]. The panel judged the claim well supported but stopped short of the top tier because the main trial measured an early signal rather than a final cure, the trials only showed dalbavancin was no worse than the comparator rather than proving a high absolute cure rate, and the word 'high' is not precisely defined.
The corpus contains two phase 3 noninferiority RCTs directly on dalbavancin in skin infection. [1] reports clinical success of 88.9% at the test-of-cure visit and >90% at end of therapy, with microbiological success in excess of 85% and relapse in less than 1.0% of patients. [3] (pooled DISCOVER 1 and 2) reports an early clinical response of 79.7% (525 of 659 patients) and clinical success of 90.6% in patients infected with Staphylococcus aureus, including MRSA. Two retrospective emergency-department cohorts corroborate real-world use: [7] reports that 16 patients (12.8%) were subsequently admitted, and [10] reports recurrence of 14% (6/42) and 22% (5/23) across its cohorts. The evidence is consistent across independent trials and sites. The contested point: The division is over what the headline figure measures: the pivotal DISCOVER endpoint [3] is early clinical response at 48 to 72 hours (cessation of spread of erythema and absence of fever), a surrogate, not a sustained or microbiological cure. Because every eligible trial is a noninferiority design against an active comparator with no placebo arm, the corpus can show dalbavancin matches comparators but cannot anchor whether cure is 'high' in absolute terms.
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Novel Antibiotics, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The DISCOVER primary endpoint in [3] is early clinical response at 48-72h (cessation of erythema spread and absence of fever), a surrogate; the headline 79.7% is not a classical sustained or microbiological cure rate.
All eligible trials are noninferiority designs against an active comparator with no placebo arm, so the corpus cannot establish that cure is 'high' in absolute terms, only non-inferior to comparators.
Where it remains uncertain. The DISCOVER primary endpoint in [3] is an early 48 to 72 hour surrogate and all trials are noninferiority designs with no placebo arm, so 'high' cannot be benchmarked absolutely.
Aleatory
Cohorts [7] and [10] show variable outcomes across patient subgroups (e.g. recurrence 14% vs 22% between cohorts in [10]), reflecting irreducible patient-to-patient variability in real-world infection severity.
Epistemic
Every trial [1], [3] is noninferiority against an active comparator with no placebo arm, so the true absolute cure rate against no-treatment is unknown from this corpus.
Inferential
The pivotal DISCOVER endpoint in [3] is early clinical response at 48 to 72 hours; inferring sustained 'cure' from this surrogate is an inferential leap the corpus does not close.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary RCT evidence of high clinical success (88.9% TOC, >90% end of therapy) in complicated SSSI.
“Dalbavancin and linezolid demonstrated comparable clinical efficacy in the clinically evaluable population at the test-of-cure visit (88.9% and 91.2% success, respectively). The rate of clinical success at the end of therapy was >90% in both arms.”
Panel auditInternal validity: high · scope of inference: Adults with complicated skin and skin structure infections (pre-ABSSSI definition), including MRSA.Key limitations: cSSSI not the FDA ABSSSI definition · comparator is linezolid not placebo · total N not stated in abstract
Pooled phase 3 ABSSSI early clinical response rate of 79.7% for dalbavancin.
“For patients infected with Staphylococcus aureus, including methicillin-resistant S. aureus, clinical success was seen in 90.6% of the patients treated with dalbavancin”
Panel auditInternal validity: high · scope of inference: Adults with acute bacterial skin and skin-structure infection, including S. aureus and MRSA.Key limitations: primary endpoint is early (48-72h) response, not end-of-therapy cure · comparator-based noninferiority not absolute threshold · industry funded
Real-world cohort support: low subsequent admission after dalbavancin for ABSSSI.
“A total of 16 patients (12.8%) were subsequently admitted to the hospital with a median length of stay of 5.5 days (3.0-8.0).”
Panel auditInternal validity: low · scope of inference: Adults receiving dalbavancin for ABSSI at one rural emergency department.Key limitations: no cure-rate endpoint · single-center retrospective · no comparator group
3 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, directly on-target phase 3 RCT evidence supports high clinical success, but surrogate-endpoint and noninferiority-design caveats keep it at Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Sustained-cure endpoint in ABSSSI. The pivotal trial's primary endpoint [3] is an early 48 to 72 hour surrogate; durable clinical and microbiological cure under the modern ABSSSI definition is not the primary measure anywhere in the corpus. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective RCT in modern-definition ABSSSI with sustained clinical cure and microbiological eradication at end of therapy and late follow-up as pre-specified primary endpoints.
Open question: Does dalbavancin's early clinical response at 48 to 72 hours translate into durable clinical and microbiological cure in modern-definition ABSSSI? Why it is still open: The pivotal DISCOVER endpoint in [3] is the early surrogate; end-of-therapy and later cure are reported only as secondary or in the older complicated-SSSI trial [1].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19